Primmune Therapeutics
Latest round
- Series B
Last raised
- Jan 2026
Total raised
- $47M
Investors
- 7
About Primmune Therapeutics
Primmune Therapeutics, Inc.Founded in 2017 and headquartered in Carlsbad, US, Primmune Therapeutics specializes in therapeutic solutions targeting the immune response against cancers associated with viral infections. The founders, Jim Appleman and Paulo Rangel, established the firm to advance oncology treatments. In January 2026, Primmune Therapeutics, Inc. Primmune Therapeutics, Inc. specializes in the development of innovative therapies targeting the activation of plasmacytoid dendritic cells (pDCs) via the toll-like receptor 7 (TLR7) pathway. Its lead clinical candidate, PRTX007, is a tuned TLR7 agonist designed for oral administration. This product uniquely stimulates a systemic immune response characterized by the production of Type I and III interferons without triggering the production of pro-inflammatory cytokines like IL-6, TNFa, or IL-1ß. The primary focus of Primmune's offerings is to address cancers associated with viral infections, particularly HPV-related oropharyngeal cancers and hepatocellular carcinoma.S.Primmune Therapeutics operates within a revenue model structured around partnerships and clinical trial agreements with healthcare institutions and research organizations. Revenue generation is anticipated through collaborations with pharmaceutical companies and potential licensing agreements for PRTX007 and other TLR7 agonists. The company’s transaction structure involves direct interactions with clinical research entities and healthcare providers, focusing on trials and assessments that can lead to regulatory approvals for its products. As Primmune advances towards clinical trials, the structure of its financial engagements may include milestone payments associated with the development and commercialization of its lead candidate, thereby fostering a robust pipeline supported by strategic partnerships in the oncology sector.
Who invested in Primmune Therapeutics
7 investors across 4 rounds
See all investors in Primmune Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Primmune Therapeutics
Who invested in Primmune Therapeutics?
Primmune Therapeutics has 7 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Primmune Therapeutics raised?
Primmune Therapeutics has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Primmune Therapeutics last raise money?
Primmune Therapeutics's most recent round on record is a Series B, in Jan 2026.
What does Primmune Therapeutics do?
Primmune Therapeutics is a biotechnology company.
Where is Primmune Therapeutics headquartered?
Primmune Therapeutics is headquartered in San Diego, US.
Which VCs invest in companies like Primmune Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Primmune Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Primmune Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.